Using exome sequences for 6,753 parent-child trios, researchers saw genes with increased de novo variant burdens in neurodevelopmental disorders with epilepsy.
The researchers also uncovered ties between the two traits and other neurological and psychological traits, such as Alzheimer's disease and depression.
This could mean that clinical boundaries between psychiatric disorders might not reflect their underlying biology, Brainstorm Consortium researchers said.
The £550,000 award is part of a larger multi-partner grant to develop and implement a point-of-care test to avoid antibiotic-related hearing loss in newborns.
A large meta-analysis and functional genomic assessment of a risky HLA haplotype uncovered hypomethylation that alters immune-related expression at the locus.
The UK-based Dementia Discovery Fund is investing $1.3M in Immuneering's drug-discovery technology in search of new molecular entities for treating Alzheimer's.
An association study involving more than 100,000 individuals led to overlapping and distinct variants involved in bipolar disorder, schizophrenia, and subtypes of each.
The designation will help the company accelerate the process of bringing the opioid addiction risk test through regulatory review and clearance.
The multi-year renewal includes DNA Genotek's Oragene-Dx saliva kits and GenoFIND services for custom collection kit packaging and order fulfillment services.
By combining iPSCs, CRISPR gene editing, and transcriptomic approaches, researchers examined the effects of an Alzheimer's disease risk variant on brain cells.
Researchers searched exome sequences of more than 100,000 individuals for associations to more than a dozen quantitative human traits and 10 diseases.
The genetic risk of schizophrenia is influenced by early-life complications and the placenta differentially expresses these complication-linked genes, a new study says.
Researchers found that individuals with unexplained neurodevelopmental disorders and congenital anomalies had an enrichment of de novo epivariations.
Researchers from A*Star and elsewhere have implicated a recessive mutation in CAMK2A in a neurodevelopmental disorder affecting a pair of siblings.
While a randomized-controlled trial is underway, Genomind hopes data from a new case-control study will convince insurers its PGx test can reduce healthcare utilization costs.
The company plans to test both its current technology and explore novel signatures using samples from Mayo's biobank.
The company hopes to replicate its early data in future studies, making a case that better early diagnosis can improve outcomes for patients with schizophrenia and bipolar disorder.
With genome-wide association study data, researchers saw enrichment for schizophrenia-linked SNPs in human-specific differentially methylated regions.
The company presented new data on the PGx test this week and expressed confidence that they can secure broader payor coverage for it.
An international team of researchers combined data from seven cohorts to uncover 30 novel depression-linked loci, including ones that overlap with schizophrenia.
In PLOS this week: transcriptomic and genomic analysis of prostate cancer by ancestry, genes linked to liver function in Korean cohort, and more.
British Columbia is incorporating genomics into its tracking of the ongoing COVID-19 outbreak, Business in Vancouver reports.
An analysis by the Personalized Medicine Coalition finds that about a quarter of new drugs approved in 2019 by the US Food and Drug Administration were personalized medicines.
The governor of New York has proposed a five-year plan to study the genomes of people with or who are at high risk of developing Alzheimer's disease.